ArticleFrontiers in cellular and infection microbiology2025
Targeted next-generation sequencing for antimicrobial resistance detection in ventilator-associated pneumonia.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- [Value of targeted next-generation sequencing in pathogen detection for neonates with respiratory distress syndrome: a prospective randomized controlled trial].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Trial
- A novel targeted hybrid capture-NGS assay for sensitive detection of multiplex respiratory pathogens.Microbiology spectrum · 2026Article
- Molecular insights into antimicrobial resistance in human bacterial pathogens: mechanisms, resistance genes, and translational diagnostic applications.Frontiers in microbiology · 2026Review
- Comparison of targeted next-generation sequencing and conventional tests for pathogen detection in community-acquired and severe community-acquired pneumonia: a retrospective cohort study.Frontiers in microbiology · 2026Article
- Enhancing upper respiratory tract infection detection: exploring qPCR negative respiratory samples using targeted next-generation sequencing.Infection · 2025Article
- Article
- Targeted next-generation sequencing for pediatric lower respiratory tract infections: a retrospective study.Frontiers in cellular and infection microbiology · 2025Article
- Targeted next-generation sequencing using bronchoalveolar lavage fluid samples for diagnosing pulmonary infections: a single-center retrospective study.Frontiers in microbiology · 2025Article
- Comparative and clinical impact of targeted next-generation sequencing in pediatric pneumonia diagnosis and treatment.Frontiers in microbiology · 2025Article
- Enhancing bloodstream infection diagnostics: a novel filtration and targeted next-generation sequencing approach for precise pathogen identification.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ventilator-associated pneumonia (VAP) carries a high mortality rate in the intensive care units (ICUs) due to its widespread drug resistance. Traditional microbial cultures limited by speed and sensitivity, are often unable to help clinicians make effective diagnosis and treatment. Therefore, there is an urgent need for a rapid and accurate test that can identify both pathogens and their antimicrobial resistance (AMR) to improve the prognosis of patients with VAP. Study design: We analyzed samples from ICU patients with suspected VAP using both microbial tests and targeted next-generation sequencing (tNGS), comparing the results of tNGS pathogen and AMR detection against microbial culture and antimicrobial susceptibility testing (AST). Results: Involving 199 patients with suspected VAP, tNGS showed a sensitivity rate of 98.98% for pathogen identification. While the sensitivity rate of microbial culture was just 66.84%. Additionally, tNGS performed almost half the turnaround time of microbial culture (1.66 days vs 3.00 days). For AMR, the overall consistency between AST and tNGS was 79.31%. The great performance particularly exhibited for Conclusion: tNGS excels in identifying pathogens and AMR. Its rapid workflow makes it ideal for managing critically ill patients, enhancing treatment precision, and reducing antibiotic misuse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.